Comparison of Fluorescence in Situ Hybridization Detection of HER-2 Gene Amplification and Immunohistochemical Detection of C-erbB-2 Protein Expression
CHEN Xu, et al
The People's Hospital of Baise, Guangxi Baise 533000, China
Abstract：Objective: To compare the differences and correlation between fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) in the detection of HER-2 gene and protein in breast cancer. Methods: Taking the surgical pathological slices of 98 breast cancer patients as the test objects, FISH and IHC were performed respectively, and the test results were analyzed. Results: IHC test results showed that 53 cases (54.08%) were positive and 45 cases (45.92%) were negative. FISH test results showed that 29 cases (29.59%) were positive and 69 cases (70.41%) were negative. With FISH as the gold standard, the coincidence rate of negative (-) for IHC is 42 (93.33%), the coincidence rate of positive (+) is 5 (17.86%), the coincidence rate of ++ is 11 (78.57%), and the coincidence rate of +++ is 10 (90.91) %). Conclusion: In IHC preliminary screening of C-erbB-2 protein, the coincidence rate of -, +++ is relatively high, and the coincidence rate of IHC in the screening of ++ and + is low. It is recommended to do FISH screening on the basis of IHC screening to clarify the HER-2 gene status.
陈煦, 陆定贵. 荧光原位杂交检测HER-2基因扩增和免疫组化技术检测C-erbB-2蛋白表达情况的比较[J]. 河北医学, 2021, 27(8): 1290-1294.
CHEN Xu, et al. Comparison of Fluorescence in Situ Hybridization Detection of HER-2 Gene Amplification and Immunohistochemical Detection of C-erbB-2 Protein Expression. HeBei Med, 2021, 27(8): 1290-1294.
[1] 黄育北,宋丰举,陈可欣.全基因组关联研究在乳腺癌筛查中的应用价值初探[J].中华流行病学杂志,2019,40(6):713~718. [2] Pourmand,Marziyeh.Breast cancer:causes and prevention[J].Journal of Cellular Immunotherapy,2017,3(1):15. [3] 骆梅青,石洁琼,徐胜源,等.miR-125a-5p靶向调控HER-2表达抑制乳腺癌细胞生物学活性[J].临床肿瘤学杂志,2019,24(6):500~505. [4] 武惠丽,李毅.多西他赛与表柔比星联合或序贯化疗治疗局部晚期乳腺癌的临床疗效研究[J].河北医学,2017,23(4):639~642. [5] Huili S,Guang L,Jing S,et al.Using bioinformatics analysis for screening for a new potential target gene in HER-2 negative breast cancer[J].Genomics and Applied Biology,2018,25(6):120~124. [6] Konigshoff M,Jochen W,Bohle RM,et al.HER-2/neu gene copy number quantified by real-time PCR:comparison of gene amplification,heterozygosity,and immunohistochemical status in breast cancer tissue[J].Clinical Chemistry,2020,49(2):219~229. [7] 武惠丽,李毅.多西他赛与表柔比星联合或序贯化疗治疗局部晚期乳腺癌的临床疗效研究[J].河北医学,2017,23(4):639~642. [8] 管枫,阎红琳,袁静萍.IHC与FISH检测乳腺癌HER2表达的差异性分析[J].中华内分泌外科杂志,2018,12(5):372~376. [9] 程弘夏,付敏,叶伦,等.三组HER-2双色探针不同杂交时间下检测乳腺癌临床样本[J].临床与实验病理学杂志,2018,34(8):928~930.
2021, Vol. 27 
冀公网安备13080202000677号